Loading...
•
Dec 31, 2020
LeMaitre Vascular Q4 2020 Earnings Report
LeMaitre Vascular reported record sales and healthy bottom-line results driven by sales growth across all regions and expense control.
Key Takeaways
LeMaitre Vascular reported Q4 2020 results with sales growth in the Americas, Asia/Pac, and Europe/Middle East/Africa. The three recent acquisitions (Artegraft, CardioCel and Eze-Sit) led growth in Q4 2020. Gross margin decreased to 65.0% due to recent acquisitions and factory transitions. Operating expenses decreased 1% due to COVID-related cost-cuts as well as reduced travel and surgeon congresses.
Posted sales growth in the Americas (+35%), Asia/Pac (+12%) and Europe/Middle East/Africa (+9%).
The three recent acquisitions (Artegraft, CardioCel and Eze-Sit) led growth in Q4 2020.
Biologic grafts, valvulotomes and embolectomy catheters drove sales.
Gross margin decreased to 65.0% in Q4 2020 (vs. 66.0% in Q4 2019) primarily due to recent acquisitions and factory transitions.
Forward Guidance
Positive Outlook
- $33.8mm - $36.8mm (Midpoint:+16%)
- $6.8mm - $8.8mm (Midpoint:+79%)
- $0.24 - $0.31 (Midpoint: +78%)
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...